Liminatus Pharma Registers 20.7M Shares for Resale by Investor, Adding to Dilution Amidst Delisting Threat
LIMN is trading near its 52-week low of $0.105 (4.7% above the low) on light trading volume (0.1× avg).
Summary
Liminatus Pharma filed an S-1 to register 20.7 million shares for resale by Armistice Capital, shares issuable from inducement warrants with an exercise price above the current market price. This comes as the company faces Nasdaq delisting and significant financial challenges, with a massive acquisition pending.
Key Events · Financing and Capital Events · LIMN
-
Registers 20.7 Million Shares for Resale
Liminatus Pharma filed an S-1 registration statement for the resale of up to 20,688,000 shares of common stock by Armistice Capital Master Fund Ltd. These shares are issuable upon the exercise of inducement warrants.
-
Inducement Warrants Exercise Price Above Market
The inducement warrants have an exercise price of $0.18 per share, which is currently above the company's stock price of $0.1104. The company may receive up to $3.72 million if these warrants are exercised for cash.
-
Follows Recent Warrant Inducement for Cash
This registration follows a June 3, 2026, inducement agreement where Armistice Capital exercised existing warrants at a reduced price of $0.18 (from $0.29), providing Liminatus Pharma with an immediate $1.86 million cash infusion.
-
Faces Nasdaq Delisting Threats
The company is currently facing formal Nasdaq delisting notices for failing to meet minimum bid price and market value requirements, with its stock trading near 52-week lows.
Analysis · LIMN · Life Sciences
This S-1 filing registers a substantial number of shares (20.7 million) for resale by a key investor, Armistice Capital, which could lead to significant dilution if the warrants become in-the-money and are exercised. This event is critical given Liminatus Pharma's precarious financial state, including a 'going concern' warning, recurring losses, and imminent Nasdaq delisting threats. The company is actively pursuing various financing strategies, including a recent warrant inducement that brought in $1.86 million, but the overall capital structure is becoming increasingly complex and dilutive, especially with a massive 1.6 billion share acquisition pending.
At the time of this filing, LIMN was trading at $0.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.11 to $33.66. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.